Hemophilus Influenzae Meningitis Treated With Streptomycin

Studies on Some Biological Aspects of Dihydrostreptomycin

“…A strain of Hemophilus influenzae, type B, grown resistant to streptomycin (Alexander et al, 1946) and an unidentified gram-negative rod described by Smith3 (1946) as being very resistant to this antibiotic were tested as to sensitivity to streptomycin and to the dihydro compound. In Levinthal's broth 25,000 units of streptomycin per ml failed to inhibit the Hemophilus culture, and 'This culture was obtained from Miss Dorothy Smith and Dr. Hans Molitor, of the Merck Institute for Therapeutic Research, to whom the authors are indebted.…”

Human Polyclonal Antibodies Prevent Lethal Zika Virus Infection in Mice

“…Notably, during the 1918 influenza pandemic, serum from recovered patients was used successfully to treat acutely ill patients 37 . The role of convalescent serum therapy expanded to many infections beyond influenza during the first half of the 20th century with clinical benefit demonstrated for other viral diseases like measles 38 and polio 39 , and for invasive bacterial pathogens, including pneumococcus, Haemophilus influenzae B , and meningococcus 40,41 . Passive immunization with antibody-based therapies has emerged as a promising strategy for treating emerging infectious diseases, and include both monoclonal (mAb) and polyclonal antibodies (pAb), each of which has its advantages and disadvantages.…”

Convalescent Plasma for Infectious Diseases: Historical Framework and Use in COVID-19

“…During the first half of the 20th century, the therapeutic role of convalescent blood products extended to other viral conditions, such as mumps [37], polio [38], and measles [39], and bacterial infections, including Haemophilus influenzae B [40], pneumococcus, and meningococcus [41] infections. Nevertheless, the use of convalescent plasma therapy to treat bacterial infections markedly declined following the discovery of antibiotics in the 1930s and was largely abandoned by the mid-1940s.…”